2024
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.
Schuetze S, Ballman K, Heise R, Ganjoo K, Davis E, George S, Burgess M, Choy E, Shepard D, Tinoco G, Hirbe A, Kelly C, Attia S, Deshpande H, Schwartz G, Siontis B, Riedel R, von Mehren M, Kozlowski E, Chen H, Astbury C, Rubin B. A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma. Clinical Cancer Research 2024, 30: 4584-4592. PMID: 38446990, PMCID: PMC11377863, DOI: 10.1158/1078-0432.ccr-23-3817.Peer-Reviewed Original ResearchEpithelioid hemangioendotheliomaMetastatic epithelioid hemangioendotheliomaMedian PFSOS ratesEvidence of tumor progressionPhase 2 trialMedian pain intensityEffects of trametinibMAPK pathwayActivation of MAPK pathwayInhibitor of MEKPalliative benefitPain intensityPain scoresPrimary endpointAssociated with reductionsTrametinibTumor progressionTumor samplesOncogenic driversVascular cancerPatientsPatient safetyResponse ratePFS
2015
Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014.
Flaig T, Tangen C, Hussain M, Agarwal N, Mitsiades N, Deshpande H, Vaishampayan U, Thompson I. Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014. Journal Of Clinical Oncology 2015, 33: 152-152. DOI: 10.1200/jco.2015.33.7_suppl.152.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalMonths of ADTInitial androgen deprivation therapyTime of enrollmentDeprivation therapyPSA responsePoor prognosisGrade 3 adverse eventsMedian progression-free survivalMetastatic prostate cancer patientsAbiraterone acetate treatmentMetastatic PC patientsSecondary hormonal therapySubsequent median survivalPhase II trialProstate cancer patientsEligible patientsUndetectable PSAALT elevationEfficacy of AAHormonal therapyII trialPrimary endpointRectal bleeding